货号 (SKU)

包装规格

是否现货

价格

数量

C412010-100μg

100μg

现货

C412010-1mg

1mg

现货

C412010-5mg

5mg

现货

C412010-10mg

10mg

期货

基本信息

产品名称	Cemiplimab (anti-PD-1), 程序性细胞死亡 1 (CD279) 抗体
别名	西米普利单抗（抗 PD-1）
英文别名	hPD-1 \| Protein PD-1
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	PDCD1
应用	ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt
种属反应性	人(Human)
偶联	Unconjugated
作用类型	抑制剂
作用机制	程序性细胞死亡 1 (CD279) 抗体

产品属性

抗体类型	Primary antibody
克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG4
轻链亚型	kappa
SDS-PAGE	26.0 kDa (Light Chain) & 49.9 kDa (Heavy Chain), under reducing conditions; 169.6 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
来源	CHO supernatant
物理外观	Liquid
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	1801342-60-8
分子类型	抗体

图片

ELISA: Cemiplimab (anti-PD-1) (C412010)

Cemiplimab (anti-PD-1) (C412010) - ELISA
Immobilized hu-PD-1 at 2 μg/mL can bind Cemiplimab (anti-PD-1) (C412010) with the EC₅₀ of 8.66 ng/mL.

SEC: Cemiplimab (anti-PD-1) (C412010)

Cemiplimab (anti-PD-1) (C412010) - SEC
The purity of Cemiplimab (anti-PD-1) (C412010) is more than 95% verified by HPLC.

ELISA: Cemiplimab (anti-PD-1) (C412010)

Cemiplimab (anti-PD-1) (C412010) - ELISA
Immobilized Recombinant Human PD-1 Protein (rp176241) at 1.0 μg/mL can bind Cemiplimab (anti-PD-1) (C412010) with the EC50 of 12.82 ng/mL.

关联靶点（人）

PDCD1 Tclin 程序性细胞死亡蛋白 1(Programmed cell death protein 1) (0 活性数据)

点击查看靶蛋白信息： PDCD1

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

PDCD1 Tclin Programmed cell death protein 1 (14 活性数据)

点击查看靶蛋白信息： PDCD1

活性类型	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

安全和危险性（GHS）

SDS英文版

技术规格说明书

技术规格说明书

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到5个结果

批号(Lot Number)	证书类型	日期	货号
ZJ24F1214854	分析证书	24-12-05	C412010
ZJ24F1214853	分析证书	24-12-05	C412010
ZJ24F1214852	分析证书	24-12-05	C412010
ZJ23F1202079	分析证书	23-12-20	C412010
ZJ23F1202078	分析证书	23-12-20	C412010

可替换产品

参考文献

1. Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, Huang TT, Poueymirou WT, Esau L, Meola M et al.. (2014) Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice.. Proc Natl Acad Sci USA, 111 (14): (5153-8). [PMID:24706856] [10.1021/op500134e]
2. Falchook GS, Leidner R, Stankevich E, Piening B, Bifulco C, Lowy I, Fury MG. (2016) Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.. J Immunother Cancer, 4 (13): (70). [PMID:27879972] [10.1021/op500134e]
3. Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q et al.. (2017) Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.. Mol Cancer Ther, 16 (5): (861-870). [PMID:28265006] [10.1021/op500134e]
4. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS et al.. (2018) PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.. N Engl J Med, 379 (4): (341-351). [PMID:29863979] [10.1021/op500134e]
5. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P et al.. (2004) The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).. Genome Res, 14 (10B): (2121-7). [PMID:15489334] [10.1021/op500134e]
6. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K et al.. (2004) Complete sequencing and characterization of 21,243 full-length human cDNAs.. Nat Genet, 36 (1): (40-5). [PMID:14702039] [10.1021/op500134e]
7. Kline J, Gajewski TF. (2010) Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.. Curr Opin Investig Drugs, 11 (12): (1354-9). [PMID:21154117] [10.1021/op500134e]
8. Hall RD, Gray JE, Chiappori AA. (2013) Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.. Cancer Control, 20 (1): (22-31). [PMID:23302904] [10.1021/op500134e]
9. Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Dömling A, Dubin G, Holak TA. (2015) Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.. Structure, 23 (12): (2341-2348). [PMID:26602187] [10.1021/op500134e]
10. L R Finger,J Pu,R Wasserman,R Vibhakar,E Louie,R R Hardy,P D Burrows,L G Billips. (1997-10-23) The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors.. Gene, 197 ((1-2)): (177-187). [PMID:9332365]
11. Cheng B, Ren Y, Niu X, Wang W, Wang S, Tu Y, Liu S, Wang J, Yang D, Liao G, Chen J.. (2020) Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents.. J Med Chem, 63 (15): (8338-8358). [PMID:32667799] [10.1021/acs.jmedchem.0c00574]
12. Shinohara, T T, Taniwaki, M M, Ishida, Y Y, Kawaichi, M M and Honjo, T T.. (1994) Structure and chromosomal localization of the human PD-1 gene (PDCD1).. Genomics, [PMID:7851902]
13. Prokunina, Ludmila L and 23 more authors.. (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans.. Nature genetics, [PMID:12402038]
14. Fife, Brian T BT and Pauken, Kristen E KE.. (2011) The role of the PD-1 pathway in autoimmunity and peripheral tolerance.. Annals of the New York Academy of Sciences, [PMID:21276005]
15. Topalian, Suzanne L SL and 29 more authors.. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.. The New England journal of medicine, (28): [PMID:22658127]
16. Cheng, Xiaoxiao X and 18 more authors.. (2013) Structure and interactions of the human programmed cell death 1 receptor.. The Journal of biological chemistry, (26): [PMID:23417675]
17. Robert, Caroline C and 27 more authors.. (2015) Nivolumab in previously untreated melanoma without BRAF mutation.. The New England journal of medicine, (22): [PMID:25399552]
18. McDermott, J J and Jimeno, A A.. (2015) Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.. Drugs of today (Barcelona, Spain : 1998), [PMID:25685857]
19. Na, Zhenkun and 6 more authors.. (2017) Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab.. Cell research, [PMID:27325296]
20. Pascolutti, Roberta R and 6 more authors.. (2016) Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant.. Structure (London, England : 1993), (4): [PMID:27618663]
21. Horita, Shoichiro S and 5 more authors.. (2016) High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1.. Scientific reports, (13): [PMID:27734966]
22. Tan, Shuguang S and 15 more authors.. (2017) An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.. Nature communications, (6): [PMID:28165004]
23. Berger, Kristin Nicole KN and Pu, Jeffrey Jiayu JJ.. (2018) PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene.. Gene, (5): [PMID:28951311]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Cemiplimab (anti-PD-1), 程序性细胞死亡 1 (CD279) 抗体

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

技术规格说明书

质检证书（CoA,COO,BSE/TSE 和分析图谱)

可替换产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器

Cemiplimab (anti-PD-1), 程序性细胞死亡 1 (CD279) 抗体

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

技术规格说明书

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器